2019
Selectively Oxidized Cellulose with Adjustable Molecular Weight for Controlled Release of Platinum Anticancer Drugs
MUNSTER, Lukas, Michaela FOJTŮ, Zdenka CAPAKOVA, Tomáš VACULOVIČ, Michaela TVRDOŇOVÁ et. al.Základní údaje
Originální název
Selectively Oxidized Cellulose with Adjustable Molecular Weight for Controlled Release of Platinum Anticancer Drugs
Autoři
MUNSTER, Lukas (203 Česká republika), Michaela FOJTŮ (203 Česká republika, domácí), Zdenka CAPAKOVA (203 Česká republika), Tomáš VACULOVIČ (203 Česká republika, domácí), Michaela TVRDOŇOVÁ (203 Česká republika, domácí), Ivo KURITKA (203 Česká republika), Michal MASAŘÍK (203 Česká republika, garant, domácí) a Jan VICHA (203 Česká republika)
Vydání
Biomacromolecules, Washington, American Chemical Society, 2019, 1525-7797
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
10608 Biochemistry and molecular biology
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 6.092
Kód RIV
RIV/00216224:14110/19:00107804
Organizační jednotka
Lékařská fakulta
UT WoS
000464248300015
Klíčová slova anglicky
NMR CHEMICAL-SHIFTS; DENSITY-FUNCTIONAL THEORY; RELATIVISTIC DOUBLE-ZETA; HYALURONIC-ACID; DIALDEHYDE CELLULOSE; TRIPLE-ZETA; BASIS-SETS; PT-195 NMR; CISPLATIN; PERIODATE
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 31. 3. 2020 22:07, Mgr. Pavla Foltynová, Ph.D.
Anotace
V originále
The synthesis of selectively oxidized cellulose, 2,3-dicarboxycellulose (DCC), is optimized for preparation of highly oxidized material for biological applications, which includes control over the molecular weight of the product during its synthesis. Conjugates of DCC and cisplatin simultaneously offer a very high drug binding efficiency (>90%) and drug loading capacity (up to 50 wt %), while retaining good aqueous solubility. The adjustable molecular weight of the DCC together with variances in drug feeding ratio allows to optimize cisplatin release profiles from delayed (<2% of cisplatin released during 6 h) to classical burst release with more than 60% of cisplatin released after 24 h. The release rates are also pH-dependent (up to 2 times faster release at pH 5.5 than at pH 7.4), which allows to exploit the acidic nature of tumor microenvironment. Extensive in vitro studies were performed on eight different cell lines for two cisplatin-DCC conjugates with different release profiles. In comparison with free cisplatin, both cisplatin-DCC conjugates demonstrated considerably lower cytotoxicity toward healthy cells. Conjugates with burst release profiles were found more effective against prostate cell lines, while DCC conjugates with slower release were more cytotoxic against ovarian and lung carcinoma cell lines. In vivo studies indicated a significantly longer survival rate, a reduction in tumor volume, and a higher accumulation of platinum in tumors of mice treated with the cisplatin-DCC conjugate in comparison to those treated by free cisplatin.
Návaznosti
| GA16-05961S, projekt VaV |
| ||
| LM2015043, projekt VaV |
| ||
| LM2015085, projekt VaV |
| ||
| MUNI/A/1255/2018, interní kód MU |
| ||
| MUNI/A/1553/2018, interní kód MU |
|